Identification of Tamoxifen-Resistant Breast Cancer Cell Lines and Drug Response Signature

Схожие документы

• A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
  по: Chen, Yanhua, et al.
  Опубликовано: (2020)
• ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway
  по: Li, Guangliang, et al.
  Опубликовано: (2020)
• Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line
  по: Gu, Xi, et al.
  Опубликовано: (2015)
• Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer
  по: Cai, Hao, et al.
  Опубликовано: (2015)
• Tamoxifen resistance and epigenetic modifications in breast cancer cell lines
  по: Badia, Eric, et al.
  Опубликовано: (2007)